Login to Your Account

Cerep Gets Mixed Results From Anticancer Drug Phase I/II Trial

By James Etheridge

Wednesday, December 28, 2005
PARIS - Cerep SA reported encouraging, but mixed, results from a proof-of-concept Phase I/II trial of a cancer drug developed by its subsidiary, Cerenis, which is being tested in refractory or relapsing acute myeloid leukemia (AML). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription